menu

The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Facebook Comments

Schedule29 Mar 2024